| 证券代码 | DRNA.O |
| 证券名称 | Dicerna Pharmaceuticals Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2014-01-30 |
| 首发价格(元) | 15 USD |
| 首发数量(股) | 6000000 |
| 首发募资额(元) | 90,000,000.00 USD |
| 首发主承销商 | Jefferies LLC,Leerink Partners LLC,Stifel Nicolaus & Company, In |
| 货币单位 | USD |
| 公司名称 | Dicerna Pharmaceuticals, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 87 Cambridgepark Drive, Cambridge, Massachusetts, USA |
| 成立日期 | 2006-10 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.dicerna.com |
| 电话 | +1 (617) 621-8097 |
| 传真 | +1 (617) 612-6298 |
| 公司简介 | Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of innovative RNAi-based therapeutics for diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. The Company is leveraging its proprietary GalXC RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. The Company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. |